Source-grounded facts extracted from Skye Bioscience, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Tu Diep departed as other_named_officer at Skye Bioscience, Inc..
“Tu Diep has entered into a previously disclosed executive employment agreement (the “ Diep Employment Agreement ”) with the Company. In connection with the Transaction, on the date hereof, the Company entered into a separation agreement with Mr. Diep (the “ Diep Separation Agreement ”) pursuant to which Mr. Diep's last day of employment with the Company will be January 31, 2027”
Punit Dhillon departed as other_named_officer at Skye Bioscience, Inc..
“Punit Dhillon has entered into a previously disclosed executive employment agreement (the “ Dhillon Employment Agreement ”) with the Company. In connection with the Transaction, on the date hereof, the Company entered into a separation agreement with Mr. Dhillon (the “ Dhillon Separation Agreement ”) pursuant to which Mr. Dhillon's last day of employment with the Company will be August 31, 2027”
Skye Bioscience, Inc.: Certificate of Amendment filed to increase authorized shares of common stock from 100,000,000 to 300,000,000 (effective 2026-05-28).
“On May 28, 2026, Skye Bioscience, Inc., a Nevada corporation (the “Company”) filed a Certificate of Amendment to the Company’s Articles of Incorporation (the “Articles”) with the Nevada Secretary of State, to amend Section 1 of Article IV of the Articles to increase the number of authorized shares of common stock, par value $0.001 per share (the “common stock”), of the Company from 100,000,000 to 300,000,000 (the “Charter Amendment”).”
Skye Bioscience, Inc. shareholders approved Proposal No. 4: The approval, on an advisory basis, of the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement. at the 2026-05-26 meeting.
“Proposal No. 4 : The approval, on an advisory basis, of the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement. The compensation of the named executive officers was approved, on an advisory basis, by the votes indicated: For Against Abstain Broker Non-Votes 12,696,055 909,925 100,318 9,823,126”
Skye Bioscience, Inc. shareholders approved Proposal No. 3: The approval of the Charter Amendment. at the 2026-05-26 meeting.
“Proposal No. 3 : The approval of the Charter Amendment. The Charter Amendment was approved by the votes indicated: For Against Abstain 20,594,286 2,875,605 59,533”
Skye Bioscience, Inc. shareholders approved Proposal No. 2: The ratification of the selection of CBIZ CPAs P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. at the 2026-05-26 meeting.
“Proposal No. 2 : The ratification of the selection of CBIZ CPAs P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The selection was ratified by the votes indicated: For Against Abstain 22,802,045 542,634 184,745”
Skye Bioscience, Inc. shareholders approved Proposal No. 1: Election of Directors at the 2026-05-26 meeting.
“Proposal No. 1: Election of Directors. The stockholders elected each of the six nominees named in the proxy statement for the 2026 Annual Meeting (the “Proxy Statement”) as members of the Board of Directors for a one-year term expiring at the Company’s 2027 annual meeting of stockholders. The results were as follows: Broker Director For Withhold Non-Votes Paul Grayson 13,194,721 511,577 9,823,126 Deborah Charych 13,293,551 412,747 9,823,126 Punit Dhillon 13,466,198 240,100 9,823,126 Annalisa Jenkins 13,491,428 214,870 9,823,126 Karen Smith 13,036,640 669,658 9,823,126 Andrew J. Schwab 13,408,440 297,858 9,823,126”
Skye Bioscience, Inc. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5450(b)(1)(A), 5810(c)(2)(C)).
“May 13, 2026 , Skye Bioscience, Inc. (the “Company” or “Skye”) received a written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based on the”
Skye Bioscience, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
“March 17, 2026 , Skye Bioscience, Inc. (the “Company” or “Skye”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock, par value $0.001 per share (the “Common Stock”) had been below the minimum $1.00 per share required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1) (“Rule 5450(a)(1)”). The Nasdaq deficiency letter has no immediate effect on the l”
Skye Bioscience, Inc. reported financial results for the fourth quarter and full year ended December 31, 2025.
“On March 10, 2026 , Skye Bioscience, Inc. (the “Company” or “Skye”) issued a press release reporting its financial results for the fourth quarter and full year ended December 31, 2025.”
Skye Bioscience, Inc. entered into Non-exclusive Collaboration and License Agreement with Halozyme, Inc. valued at milestone payments tied to achievement of certain development and commercialization milestone events (effective 2025-12-18).
“On December 18, 2025, Skye Bioscience, Inc. (the “Company”) entered into a Non-exclusive Collaboration and License Agreement (the “Agreement”) with Halozyme, Inc. (“Halozyme”).”
Skye Bioscience, Inc. engaged CBIZ CPAs P.C. as its auditor.
“☐ Item 4.01 Changes in Registrant's Certifying Accountant Based on information provided by Marcum LLP (“Marcum”), CBIZ CPAs P.C. (“CBIZ CPAs”) acquired the attest business of Marcum, effective November 1, 2024. On June 9, 2025, Marcum resigned as the independent registered public accounting firm of Skye Bioscience, Inc. (the “Company”). On June 9, 2025, the audit committee of the Company's board of directors (the "Board of Directors") engaged CBIZ CPAs as the Company’s independent registered public accounting firm for the year ending December 31, 2025, effective immediately.”
Marcum LLP resigned as auditor of Skye Bioscience, Inc..
“On June 9, 2025, Marcum resigned as the independent registered public accounting firm of Skye Bioscience, Inc.”
Puneet S. Arora was appointed as Chief Medical Officer at Skye Bioscience, Inc..
“On September 3, 2024, Skye Bioscience, Inc. (the “Company”) announced the appointment of Puneet S. Arora, MD, MS, FACE, as Chief Medical Officer, effective as of September 3, 2024 (the “Effective Date”).”
Praveen Tyle, PhD resigned as Director at Skye Bioscience, Inc..
“On July 1, 2024, each of Keith Ward, PhD and Praveen Tyle, PhD informed the Board of their intent to resign as a member of the Board, effective August 1, 2024.”
Keith Ward, PhD resigned as Director at Skye Bioscience, Inc..
“On July 1, 2024, each of Keith Ward, PhD and Praveen Tyle, PhD informed the Board of their intent to resign as a member of the Board, effective August 1, 2024.”
Karen L. Smith MD, PhD, MBA, LLM was appointed as Director at Skye Bioscience, Inc..
“the Board approved an increase in its authorized size from eight to nine members and appointed Karen L. Smith MD, PhD, MBA, LLM to fill the vacancy created by such increase.”
Skye Bioscience, Inc. amended Amendment with certain investors (effective 2024-03-11).
“Concurrently and in connection with the Private Placement, the Company entered into an amendment (the “Amendment”) to the warrants issued pursuant to that certain Securities Purchase Agreement, dated August 15, 2023, by and between the Company and certain investors (the “2023 PIPE Warrants”).”
Skye Bioscience, Inc. entered into Registration Rights Agreement with the Investors (effective 2024-03-11).
“On March 11 , 2024, concurrently and in connection with the execution of the Purchase Agreement, the Company entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with the Investors, pursuant to which the Investors will have certain customary registration rights, and the Company will be required to prepare and file a resale registration statement (the “Registration Statement”) with the SEC to register the resale of the Shares and the Warrant Shares within 60 days after the date of the Registration Rights Agreement (the “Filing Date”), and to use reasonable best efforts to have the Registration Statement declared effective as promptly as possible thereafter, and in any event no later than 30 days following the Filing Date (or 60 days following the Filing Date in the event the SEC reviews and has written comments to the Registration Statement).”
Skye Bioscience, Inc. entered into Securities Purchase Agreement with certain institutional investors valued at $40,000,000 (effective 2024-03-11).
“On March 11 , 2024, Skye Bioscience, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional investors (collectively, the “Investors”) to issue and sell at closing an aggregate of 4,000,000 shares (the “Shares”) of common stock of the Company, par value $0.001 per share (the “Common Stock”), at a price of $ 10.00 per Share (the "Private Placement").”
Margaret Dalesandro resigned as Director at Skye Bioscience, Inc..
“Margaret Dalesandro, Ph.D. informed the Board of her intent to resign as a member of the Board, effective August 1, 2024.”
Annalisa Jenkins was appointed as Director at Skye Bioscience, Inc..
“appointed Annalisa Jenkins, M.B.B.S., F.R.C.P. to fill the vacancy created by such increase.”
Skye Bioscience, Inc. entered into Securities Purchase Agreement with certain institutional investors valued at $50,249,991 (effective 2024-01-29).
“On January 29, 2024, Skye Bioscience, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional investors (collectively, the “Investors”) to issue and sell at closing (i) an aggregate of 11,822,124 shares (the “Shares”) of common stock of the Company, par value $0.001 per share (the “Common Stock”), at a price of $2.305 per Share and (ii) pre-funded warrants (the “Pre-Funded Warrants” and together with the Shares, the “Closing Securities”) to purchase up to 9,978,739 shares of Common Stock (the “Warrant Shares” and together with the Shares and the Pre-Funded Warrants, the “Securities”), at a price of $2.3049 per Pre-Funded Warrant (the “Private Placement”).”
Skye Bioscience, Inc. terminated Restated and Amended License Agreement with University of Mississippi valued at termination effective January 30, 2024 (effective 2023-12-01).
“On December 1, 2023, the Company notified the University of Mississippi (“UM”) that the Company was terminating, in its entirety, that certain Restated and Amended License Agreement, dated as of May 24, 2019, by and between the Company and UM (the “UM 8930 License Agreement”). In accordance with the terms of the UM 8930 License Agreement, the termination of such agreement will be effective on January 30, 2024 (the “Termination Date”).”
Skye Bioscience, Inc. entered into Offer to Sell with Tab Labs Inc. valued at purchase price CAD $1,499,000 (effective 2023-11-29).
“On November 29, 2023, Avalite Sciences, Inc., a wholly-owned subsidiary of the Company (“Avalite”) entered into an Offer to Sell (the “Offer to Sell”) with Tab Labs Inc. (the “Purchaser”) and Colliers Macaulay Nicolls Inc. (the “Agent”), pursuant to which Avalite agreed to sell to the Purchaser the Avalite property located at Unit 104 – 9295 198th Street, Langley, British Columba V1M 3J9, Canada (the “Property”) for a purchase price of CAD $1,499,000.”
Skye Bioscience, Inc. entered into Exclusive License Agreement with Tautomer Bioscience (Pty) Limited valued at potential milestone payments up to $10,750,000; tiered royalties up to mid-double digits; minimum $5 (effective 2023-11-30).
“On November 30, 2023, Skye Bioscience, Inc., a Nevada corporation (the “Company”) entered into an Exclusive License Agreement (the “License Agreement”) with Tautomer Bioscience (Pty) Limited (“Tautomer”), pursuant to which, among other things, the Company granted to Tautomer an exclusive license to develop, manufacture and commercialize one or more products containing the Company’s proprietary amino acid ester prodrug of delta-9-tetrahydrocannabinol”
Skye Bioscience, Inc.: Increased authorized shares of common stock from 20,000,000 to 100,000,000 (effective 2023-11-06).
“On November 6, 2023, Skye Bioscience, Inc., a Nevada corporation (the "Company") filed a Certificate of Amendment to the Company's Articles of Incorporation (the “Articles”), to amend Section 1 of Article IV of the Articles to increase the number of authorized shares of common stock from 20,000,000 to 100,000,000 (the “Charter Amendment”).”
Skye Bioscience, Inc.: Reverse stock split at a ratio of one-for-250 and reduction of authorized shares from 5,000,000,000 to 20,000,000, effective via Certificate of Change and Certificate of Correction (effective 2023-09-08).
“On September 6, 2023, Skye Bioscience, Inc. (the “Company”) filed a Certificate of Change and Certificate of Correction with the Secretary of State of the State of Nevada, which will effect a reverse stock split (the “Reverse Split”), at a ratio of one-for-250, of the Company’s issued and outstanding shares of common stock, par value $0.001 per share (the “Common Stock”).”
Paul Grayson was appointed as Director at Skye Bioscience, Inc..
“Andrew Schwab and Paul Grayson were appointed to the Board.”
Andrew Schwab was appointed as Director at Skye Bioscience, Inc..
“Andrew Schwab and Paul Grayson were appointed to the Board.”
Skye Bioscience, Inc. completed an acquisition involving Bird Rock Bio, Inc. for 968,973,005 shares of the common stock of the Company, valued at approximately $20.0 million (closed 2023-08-18).
“Pursuant to the Merger Agreement, at the effective time of the Merger (the “Effective Time”), the Company issued to certain former stockholders of Bird Rock, an aggregate of 968,973,005 shares of the common stock of the Company, par value $0.001 per share (the “Common Stock”), valued at approximately $20.0 million based on the 60 trading day volume weighted”
Paul Grayson was appointed as Director at Skye Bioscience, Inc..
“In accordance with the closing of the Merger, Andrew Schwab and Paul Grayson were appointed to the Board.”
Andrew Schwab was appointed as Director at Skye Bioscience, Inc..
“In accordance with the closing of the Merger, Andrew Schwab and Paul Grayson were appointed to the Board.”
Skye Bioscience, Inc. terminated Amended and Restated Multi-Draw Credit Agreement with Emerald Health Sciences, Inc. valued at Terminated in its entirety per the terms of the MTA following conversion of remaining balance (effective 2023-02-22).
“Following the issuance of shares described above, the Credit Agreement was terminated in its entirety per the terms of the MTA.”
Skye Bioscience, Inc. entered into Master Transaction Agreement with Emerald Health Sciences, Inc. valued at Exercise of 16,641,486 warrants at aggregate exercise price of $282,905 paid via reduction in debt; (effective 2023-02-16).
“Item 1.01 Entry into a Material Definitive Agreement. Effective February 16, 2023, Skye Bioscience, Inc. (the " Company ") and Emerald Health Sciences, Inc. (" Sciences ") entered into a master transaction agreement (the " MTA ").”
Deborah Charych was elected as Director at Skye Bioscience, Inc..
“On February 14, 2023, the Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, elected Dr. Deborah Charych, Ph.D. to fill the vacancy created by Mr. Rai's resignation.”
Bobby Rai resigned as Director at Skye Bioscience, Inc..
“On February 14, 2023, Bobby Rai resigned as a member of the Board of Directors (the "Board") of Skye Bioscience, Inc. (the "Company") and the Nominating and Corporate Governance Committee of the Board.”
Skye Bioscience, Inc. completed a disposition involving C3 Souvenir Holding, Inc. for approximately USD$9,478,000 (closed 2023-02-09).
“acquire all of the outstanding shares of Verdélite Sciences, Inc., the holder of EHT's most significant real estate asset, for an aggregate purchase price of approximately USD$9,478,000, subject to certain adjustments. To facilitate the closing of the transactions contemplated by the Verdélite SPA, on February 9, 2023, EHT, the Purchaser and certain other related”
Skye Bioscience, Inc. amended Verdélite SPA with C3 Souvenir Holding, Inc. and certain other related parties valued at approximately USD$9,478,000 (effective 2023-02-09).
“on February 9, 2023, EHT, the Purchaser and certain other related parties entered into a second amendment to the Verdélite SPA (the "Second Amendment")”
Skye Bioscience, Inc. amended SPA Amendment with C3 Souvenir Holding, Inc. (Purchaser) and certain other related parties valued at approximately USD$30,000 (effective 2023-01-26).
“On January 26, 2023, EHT, Purchaser, and certain other related parties entered into an amendment to the Verdélite SPA (the "SPA Amendment")”
Skye Bioscience, Inc. amended Credit Agreement Amendment with Emerald Health Sciences, Inc. (effective 2022-12-30).
“On December 30, 2022, Skye Bioscience, Inc. (the "Company") entered into Amendment No. 5 (the "Credit Agreement Amendment") to the Amended and Restated Multi Draw Credit Agreement (as amended, the "Credit Agreement") with Emerald Health Sciences, Inc. ("Sciences").”
Skye Bioscience, Inc. entered into Registration Rights Agreement with Emerald Health Sciences, Inc. (effective 2022-12-14).
“On December 14, 2022, Skye Bioscience, Inc. (the "Company") and Emerald Health Sciences, Inc. ("Sciences") entered into a piggyback registration rights agreement (the "Registration Rights Agreement") pursuant to which, among other things, the Company has agreed to provide registration rights for the shares of common stock underlying the warrants to purchase Company common stock held by Sciences should the Company file a registr ation statement with the SEC for the purpose of effecting a public offering of common stock.”
Skye Bioscience, Inc. amended Amendment and Acknowledgement Agreement with Emerald Health Sciences, Inc. (effective 2022-11-17).
“On November 17, 2022, Skye Bioscience, Inc. (the "Company") entered into an Amendment and Acknowledgement Agreement (the "Amendment Agreement") with Emerald Health Sciences, Inc. ("Emerald").”
Jim Heppell resigned as Director at Skye Bioscience, Inc..
“On May 18, 2022, Jim Heppell resigned as a member of Skye’s board of directors, audit committee, compensation committee, and nominating and corporate governance committee.”
Keith Ward was elected as Director at Skye Bioscience, Inc..
“elected Dr. Keith Ward, Ph.D. to fill such vacancy and serve as a director”
Kaitlyn Arsenault was appointed as Chief Financial Officer at Skye Bioscience, Inc..
“On October 4, 2021, the Board of Directors of the Company (the “Board”) appointed Kaitlyn Arsenault as the new Chief Financial Officer of the Company, effective immediately.”
Punit Dhillon resigned as interim Principal Accounting Officer at Skye Bioscience, Inc..
“As of October 4, 2021, Punit Dhillon has tendered his resignation from his position as the interim Principal Accounting Officer of Skye Bioscience, Inc. (the “Company”).”
Punit Dhillon changed role as Principal Accounting Officer at Skye Bioscience, Inc..
“Punit Dhillon, Chief Executive Officer, President, Secretary, Chair of the Board, and Director of the Company, will serve as the principal accounting officer until a successor is appointed.”
Richard Janney resigned as Principal Accounting Officer at Skye Bioscience, Inc..
“As such, Richard Janney, the Company's Principal Accounting Officer engaged through RoseRyan, has tendered his resignation with the Company.”
Praveen Tyle was elected as Director at Skye Bioscience, Inc..
“Effective July 22, 2021, the Board of Directors (the “Board”) of Skye Bioscience, Inc., a Nevada corporation (the “Company”) increased the size of the Board from three to four directors and elected Dr. Praveen Tyle, Ph.D. to fill such vacancy and serve as a director”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.